Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
- Recognition of her pioneering gene therapy research
- Coordinated the first ever gene therapy clinical trial utilizing AAVs as a vector for the treatment of an inherited liver metabolic disease for acute intermittent porphyria
- Her work on AAVs has been instrumental in creating Vivet’s research platform and advancing development of Vivet’s lead gene therapy for Wilson’s Disease
Paris, France, July 16, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is delighted to announce that its Co-Founder & Chief Scientific Officer, Dr Gloria Gonzalez-Aseguinolaza, PhD, has been honored with the Rosalind Franklin Society (RFS) Special Award in Science given by Mary Ann Liebert, Inc. and the Rosalind Franklin Society. The prestigious award recognizes Dr Gonzalez-Aseguinolaza’s remarkable contributions and dedication to advancing scientific knowledge.
